Andrew D. Simmons

9.0k total citations
60 papers, 1.2k citations indexed

About

Andrew D. Simmons is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew D. Simmons has authored 60 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 19 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew D. Simmons's work include PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Treatment and Research (9 papers). Andrew D. Simmons is often cited by papers focused on PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Treatment and Research (9 papers). Andrew D. Simmons collaborates with scholars based in United States, United Kingdom and France. Andrew D. Simmons's co-authors include Thomas C. Harding, Karin Jooss, Melinda VanRoey, Minh Nguyen, Guang Huan Tu, Betty Li, Rodney A. Prell, Bo Luan, Alshad S. Lalani and Kathryn Koprivnikar and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Andrew D. Simmons

59 papers receiving 1.2k citations

Peers

Countries citing papers authored by Andrew D. Simmons

Since Specialization

Citations

This map shows the geographic impact of Andrew D. Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Simmons more than expected).

Fields of papers citing papers by Andrew D. Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Simmons. The network helps show where Andrew D. Simmons may publish in the future.

Co-authorship network of co-authors of Andrew D. Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Simmons. A scholar is included among the top collaborators of Andrew D. Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Simmons. Andrew D. Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. 2025 ·Journal of Clinical Oncology ·Laurence Albigès, Robert J. Motzer, (unknown), Ravindran Kanesvaran, (unknown), Melissa A. Reimers, Juan Pablo Sade, Damien Pouessel, Elisa Biscaldi, Emilio Esteban, Jóse Ángel Arranz Arija, Scott S. Tykodi, Haijun Ma, Lei Zhou, (unknown), Andrew D. Simmons, Fatima Rangwala, David A. Braun, Toni K. Choueiri, Thomas Powles	5
2	LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study 2024 ·Annals of Oncology ·Neeraj Agarwal, Arun Azad, (unknown), (unknown), Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Marinos Tsiatas, Scott North, Evangelos Bournakis, (unknown), (unknown), (unknown), Andrew D. Simmons, Roberta Ferraldeschi, (unknown), (unknown)	4
3	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib 2022 ·Clinical Pharmacokinetics ·Mingxiang Liao, (unknown), Heidi Giordano, Thomas C. Harding, Lara Maloney, Andrew D. Simmons, Jim Xiao	8
4	659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2 2020 ·Annals of Oncology ·S. Chowdhury, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard Bambury, Éric Voog, Jie Zhang, Michelle Green, (unknown), Darrin Despain, Andrew D. Simmons, Simon P. Watkins, (unknown), Jim Xiao, Wassim Abida	2
5	Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies 2019 ·Cancer Research ·(unknown), Jeremy Shapiro, Ray McDermott, Josep M. Piulats, Alison Reid, Peter Ostler, Jingsong Zhang, David Campbell, Dominique Spaëth, Ivor Percent, Arif Hussain, Andrew D. Simmons, Tony Golsorkhi, Simon P. Watkins, Andrea Loehr, Simon Chowdhury, Wassim Abida	1
6	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor 2018 ·Clinical Lung Cancer ·Elena Helman, Minh Nguyen, Chris Karlovich, Darrin Despain, (unknown), Alexander I. Spira, Helena A. Yu, D. Ross Camidge, Thomas C. Harding, Richard B. Lanman, Andrew D. Simmons	52
7	Prognostic impact of loss of heterozygosity in uterine serous carcinoma 2018 ·Gynecologic Oncology ·(unknown), Eman Abdulfatah, Andrea Loehr, Andrew D. Simmons, Robert Morris, Rouba Ali‐Fehmi	0
8	ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). 2018 ·Journal of Clinical Oncology ·Petros Grivas, (unknown), Kenton Wride, (unknown), Andrea Loehr, Andrew D. Simmons, Simon Chowdhury	3
9	The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) 2017 ·Annals of Oncology ·S. Chowdhury, Wassim Abida, (unknown), Gedske Daugaard, Karim Fizazi, (unknown), Axel Heidenreich, (unknown), Ray McDermott, Axel S. Merseburger, J.M. Piulats Rodriguez, Brieuc Sautois, Srikala S. Sridhar, Cora N. Sternberg, Simon P. Watkins, Andrew D. Simmons, Surekha D Shetty, (unknown), Charles J. Ryan, Howard I. Scher	2
10	Inactivation of Capicua drives cancer metastasis 2016 ·Nature Genetics ·Ross A. Okimoto, Frank Breitenbuecher, Victor Olivas, Wei Wu, Beatrice Gini, Matan Hofree, Saurabh Asthana, Gorjan Hrustanovic, Jennifer C. Flanagan, Asmin Tulpule, Collin M. Blakely, Henry J. Haringsma, Andrew D. Simmons, Kyle Gowen, James Suh, Vincent A. Miller, Siraj M. Ali, Martin Schüler, Trever G. Bivona	117
11	Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma 2015 ·Clinical Cancer Research ·Minh Nguyen, Shuichi Miyakawa, Junichi Kato, Toshiyuki Mori, (unknown), Mark Armanini, Karen Gelmon, Rinat Yerushalmi, Samuel Leung, Dongxia Gao, Gregory M. Landes, Mary Haak‐Frendscho, (unknown), Andrew D. Simmons	19
12	Not just another paediatric neck lump: metastatic cribriform adenocarcinoma of the palate in an adolescent 2015 ·The Journal of Laryngology & Otology ·Arjun Takhar, Andrew D. Simmons, (unknown), Nicholas Hyde	9
13	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity 2008 ·Cancer Immunology Immunotherapy ·Andrew D. Simmons, Марина Москаленко, (unknown), Jianmin Fang, (unknown), Melinda VanRoey, James P. Allison, Karin Jooss	47
14	An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo 2007 ·Molecular Therapy ·Jianmin Fang, (unknown), Andrew D. Simmons, Guang Huan Tu, Minh Nguyen, Thomas C. Harding, Melinda VanRoey, Karin Jooss	84
15	The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration 2006 ·Cancer Immunology Immunotherapy ·Rodney A. Prell, (unknown), Andrew D. Simmons, Melinda VanRoey, Karin Jooss	26
16	Efficient Tet-Dependent Expression of Human Factor IX in Vivo by a New Self-Regulating Lentiviral Vector 2005 ·Molecular Therapy ·Elisa Vigna, Mario Amendola, Fabrizio Benedicenti, Andrew D. Simmons, Antonia Follenzi, Luigi Naldini	54
17	Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation 2004 ·Gene Therapy ·(unknown), Andrew D. Simmons, Melanie J. Tuerk, (unknown), Gábor Veres	40
18	Physical and transcriptional map of the critical region for keratolytic winter erythema (KWE) on chromosome 8p22-p23 between D8S550 and D8S1759 2002 ·European Journal of Human Genetics ·Silke Appel, Matthias Filter, André Reis, Hans Christian Hennies, (unknown), Emma Ogilvie, (unknown), Andrew D. Simmons, Michael Lovett, (unknown), Michèle Ramsay, Kathrin Reichwald, Wolfgang Zimmermann, André Rosenthal	8
19	Neurogenin2 Expression in Ventral and Dorsal Spinal Neural Tube Progenitor Cells Is Regulated by Distinct Enhancers 2001 ·Developmental Biology ·Andrew D. Simmons, (unknown), (unknown), Jane E. Johnson	46
20	Physical Map and Characterization of Transcripts in the Candidate Interval for Familial Chondrocalcinosis at Chromosome 5p15.1 1999 ·Genomics ·(unknown), (unknown), Teresa D. Gallardo, Andrew D. Simmons, (unknown), (unknown), Eileen L. Considine, (unknown), (unknown), Deborah Grady, Roger Cox, (unknown), Michael Lovett, Joan Overhauser, Carmen J. Williams	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact